Velocity Clinical Research, Austin

Cedar Park, Texas 78759

1 studies enrolling now · 11 studies all time

What they study most

Asthma, Chikungunya Virus, Chikungunya Virus Infection, Cytomegalovirus Infection, Episodic Migraine, Genital Herpes, Metabolic Dysfunction-Associated SteatoHepatitis (MASH), Migraine, NASH - Nonalcoholic Steatohepatitis, Pneumococcal Disease, Respiratory Syncytial Virus Infections

Studies at this site

• A Study of BLB-201 RSV Vaccine in Infants and Children — Recruiting now
• A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition — Recruiting now
• Long-term Follow-up Study to Evaluate Safety and Immunogenicity of CHIKV VLP Single or Booster Vaccination — Running, not enrolling
• A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 ) — Running, not enrolling
• A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes — Completed
• A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age — Stopped early
• A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma — Completed
• A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 (CHIKV VLP Vaccine) — Completed
• A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine — Completed
• Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults — Completed
• Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age — Completed